Influenza A Clinical Trial
Official title:
A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single-Ascending and Multiple-Ascending Doses of the Influenza A Virus Replication Inhibitor CC-42344
CC-42344 Phase 1 study with single-ascending dose (SAD) and multiple-ascending dose (MAD) parts.
This study is testing the safety, tolerability, and pharmacokinetics (PK, the amount of study drug in the blood) of a new drug called CC-42344. Up to 56 healthy men or women aged between 18-55 will be enrolled in this study in two parts. Part 1 will involve a single-ascending (increasing) dose (SAD) where 32 participants (4 groups of 8) will be assigned randomly to receive a single oral dose of the study drug or placebo. The placebo will look the same as the study drug but will not contain any medicine. Part 2: will involve a multiple-ascending dose (MAD) where 24 participants (3 groups of 8) will be randomised to receive an oral dose of study drug or placebo given once a day for 14 days. The placebo will look the same as the study drug but will not contain any medicine. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03999554 -
Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines
|
Phase 1 | |
| Completed |
NCT02487173 -
Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B
|
N/A | |
| Completed |
NCT01701752 -
Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults
|
Phase 1 | |
| Enrolling by invitation |
NCT03207152 -
Biomarkers Predicting Infectivity in an Experimental Human Influenza Model
|
Phase 1 | |
| Active, not recruiting |
NCT05567783 -
A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A
|
Phase 2 | |
| Not yet recruiting |
NCT00987012 -
The Influence of Fortified Pomegranate Juice (Punica Granatum) on Seasonal Influenza and Swine Flu Patients
|
N/A | |
| Completed |
NCT03651544 -
The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac
|
Phase 1 | |
| Completed |
NCT02623322 -
A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults
|
Phase 2 | |
| Completed |
NCT03196661 -
Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population
|
Phase 1 | |
| Completed |
NCT05163730 -
Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel
|
N/A | |
| Recruiting |
NCT05354115 -
Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.
|
N/A | |
| Completed |
NCT02014870 -
Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT02767414 -
Validation of the Ellume® Respirio Flu Test and the Ellume® eLab Flu Test for the Rapid Identification of Influenza A/B
|
N/A | |
| Completed |
NCT00922259 -
Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7
|
Phase 1 | |
| Recruiting |
NCT03238612 -
Flufenamic Acid for Hospitalised Influenza Infection
|
Phase 2 | |
| Completed |
NCT04653727 -
Effects of Integrative Medicine on Infectious Respiratory Diseases Including COVID-19
|
||
| Active, not recruiting |
NCT05268939 -
Performance Evaluation of the LumiraDx SARS-CoV-2 & FLU A/B and SARS-CoV-2 & RSV Tests for Aid in the Assessment of COVID-19
|
N/A | |
| Terminated |
NCT03376321 -
A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection
|
Phase 3 | |
| Completed |
NCT03040141 -
Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A
|
Phase 2 | |
| Terminated |
NCT03381196 -
A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications
|
Phase 3 |